Brokerages forecast that Obalon Therptcs (NASDAQ:OBLN) will announce $1.77 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Obalon Therptcs’ earnings. The highest sales estimate is $1.80 million and the lowest is $1.73 million. The business is scheduled to issue its next earnings report on Wednesday, August 9th.

On average, analysts expect that Obalon Therptcs will report full-year sales of $1.77 million for the current fiscal year, with estimates ranging from $9.20 million to $9.63 million. For the next financial year, analysts expect that the company will report sales of $21.10 million per share, with estimates ranging from $18.19 million to $24.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Obalon Therptcs.

Obalon Therptcs (NASDAQ:OBLN) last posted its quarterly earnings results on Wednesday, May 10th. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.14. The company had revenue of $1.47 million for the quarter, compared to the consensus estimate of $1.60 million.

A number of research analysts have commented on OBLN shares. BTIG Research reaffirmed a “buy” rating and issued a $20.00 target price on shares of Obalon Therptcs in a research report on Sunday, March 19th. Canaccord Genuity reaffirmed a “buy” rating on shares of Obalon Therptcs in a research report on Monday, April 17th. Zacks Investment Research cut shares of Obalon Therptcs from a “buy” rating to a “hold” rating in a research report on Wednesday, April 26th. ValuEngine raised shares of Obalon Therptcs from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, Northland Securities started coverage on shares of Obalon Therptcs in a research report on Wednesday, June 21st. They issued an “under perform” rating and a $6.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $14.20.

A number of hedge funds have recently modified their holdings of OBLN. Massachusetts Financial Services Co. MA raised its stake in shares of Obalon Therptcs by 15.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 625,729 shares of the company’s stock worth $6,689,000 after buying an additional 85,594 shares during the period. Kornitzer Capital Management Inc. KS raised its stake in Obalon Therptcs by 0.7% in the first quarter. Kornitzer Capital Management Inc. KS now owns 420,335 shares of the company’s stock worth $4,493,000 after buying an additional 3,105 shares during the last quarter. C WorldWide Group Holding A S raised its stake in Obalon Therptcs by 97.8% in the first quarter. C WorldWide Group Holding A S now owns 197,805 shares of the company’s stock worth $2,115,000 after buying an additional 97,805 shares during the last quarter. William Blair Investment Management LLC purchased a new stake in Obalon Therptcs during the first quarter worth $1,311,000. Finally, Formula Growth Ltd. raised its stake in Obalon Therptcs by 45.3% in the first quarter. Formula Growth Ltd. now owns 108,998 shares of the company’s stock worth $1,165,000 after buying an additional 34,000 shares during the last quarter. Institutional investors own 61.63% of the company’s stock.

Obalon Therptcs (NASDAQ:OBLN) remained flat at $9.03 on Friday. The stock had a trading volume of 9,025 shares. The firm’s market cap is $151.63 million. The company’s 50-day moving average is $10.30 and its 200 day moving average is $10.06. Obalon Therptcs has a 52 week low of $8.27 and a 52 week high of $15.88.

ILLEGAL ACTIVITY WARNING: “$1.77 Million in Sales Expected for Obalon Therptcs (OBLN) This Quarter” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/07/1-77-million-in-sales-expected-for-obalon-therptcs-obln-this-quarter-updated-updated-updated.html.

Obalon Therptcs Company Profile

Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

Get a free copy of the Zacks research report on Obalon Therptcs (OBLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related stocks with our FREE daily email newsletter.